StockData

Insmed vs Royalty Pharma

INSM and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and RPRX compare

Royalty Pharma is the larger company, worth 1.5 times as much as Insmed ($39.5B against $26.7B).

Insmed grew revenue faster over the last twelve months (240% versus 10.0% for Royalty Pharma).

Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 32.1% compared with −39.9% at Insmed.

Royalty Pharma pays a dividend yielding 1.4%; Insmed does not pay one.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMRPRX
Size and price
Market cap$26.7B$39.5B
Share price$121.86$68.68
Change, 1 year−36.9%75.4%
Change, 5 years321%64.0%
Beta (5Y)0.840.04
Employees1,664100
StockData Score
Total score88
Valuation score00
Growth score3 (better)2
Performance score22
Health score3 (better)2
Dividend score02 (better)
Valuation
P/E–39.0×
P/S17.6×15.6× (better)
P/B36.8×–
EV/EBITDA–33.5×
PEG–0.24
FCF yield−2.3%–
Fair value$61.10$45.76
Margin of safety−99.5%−50.1% (better)
Growth
Revenue growth (TTM)240% (better)10.0%
Revenue growth, 5Y average29.8% (better)2.3%
Net income growth (TTM)–−20.4%
EPS growth (TTM)–−19.3%
EPS growth, 5Y average–6.2%
Profitability
Gross margin84.4%–
Operating margin−37.1%59.6% (better)
Net margin−39.9%32.1% (better)
FCF margin−41.3%–
Return on equity−72.5%–
Financial health
Debt / equity0.76–
Net debt / EBITDA–5.37
Interest coverage−6.9×4.2× (better)
Current ratio2.86 (better)2.80
Altman Z-score7.42 (better)2.98
Piotroski F-score45 (better)
Dividends and buybacks
Dividend yield–1.4%
Buyback yield–0.81%
Shareholder yield0.00%2.2% (better)
Ownership
Held by institutions102%63.8%
Held by insiders0.89%22.6%
Insider net buying, 12 months−$133M−$82.2M (better)
Superinvestors holding12 (better)
Short interest, % of float6.5%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.